|
1
|
Le Blanc K, Frassoni F, Ball L, Locatelli
F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger
M, et al: Mesenchymal stem cells for treatment of
steroid-resistant, severe, acute graft-versus-host disease: A phase
II study. Lancet. 371:1579–1586. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vojtassak J, Danisovic L, Kubes M, Bakos
D, Jarabek L, Ulicna M and Blasko M: Autologous biograft and
mesenchymal stem cells in treatment of the diabetic foot. Neuro
Endocrinol Lett. 27 Suppl 2:S134–S137. 2006.
|
|
3
|
Guiducci S, Porta F, Saccardi R, Guidi S,
Ibba-Manneschi L, Manetti M, Mazzanti B, DalPozzo S, Milia AF,
Bellando-Randone S, et al: Autologus mesenchymal stem cells foster
revascularization of ischemic limbs in systemic sclerosis: A case
report. Ann Intern Med. 153:650–654. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bordignon C, Carlo-Stella C, Colombo MP,
De Vincentiis A, Lanata L, Lemoli RM, Locatelli F, Olivieri A,
Rondelli D, Zanon P and Tura S: Cell therapy: Achievements and
perspectives. Haematologica. 84:1110–1149. 2011.
|
|
5
|
Phinney DG and Prockop DJ: Concise review:
Mesenchymal stem/multipotent stromal cells: The state of
transdifferentiation and modes of tissue repair-current views. Stem
Cells. 25:2896–2902. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Poll D, Parekkadan B, Cho CH,
Berthiaume F, Nahmias Y, Tilles AW and Yarmuch ML: Mesenchymal stem
cell-derived molecules directly modulate hepatocellular death and
regeneration in vitro and in vivo. Hepatology. 47:1634–1643. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shi M, Liu ZW and Wang FS:
Immunomodulatory properties and therapeutic application of
mesenchymal stem cells. Clin Exp Immunol. 164:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han KH, Ro H, Hong JH, Lee EM, Cho B, Yeom
HJ, Kim MG, Oh KH, Ahn C and Yang J: Immunosuppressive mechanisms
of embryonic stem cells and mesenchymal stem cells in alloimmune
response. Transpl Immunol. 25:7–15. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bassi E, Aita CA and Câmara NO: Immune
regulatory properties of multipotent mesenchymal stromal cells:
Where do we stand? World J Stem Cells. 3:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cui J, Wahl RL, Shen T, Fisher SJ, Recker
E, Ginsburg D and Long MW: Bone marrow cell trafficking following
intraveneous administration. Br J Haematol. 107:895–902. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ankrum J and Karp JM: Mesenchymal stem
cell therapy: Two steps forward, one step back. Trends Mol Med.
16:203–209. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Allison M: Genzyme back Osiris, despite
Prochymal flop. Nat Biotechnol. 27:966–967. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Spaggiari GM, Capobianco A, Becchetti S,
Mingari MC and Moretta L: Mesenchymal stem cell-natural killer cell
interactions: Evidence that activated NK cells are capable of
killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell
proliferation. Blood. 107:1484–1490. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nauta AJ, Westerhuis G, Kruisselbrink AB,
Lurvink EG, Willemze R and Fibbe WE: Donor-derived mesenchymal stem
cells are immunogenic in an allogeneic host and stimulate donor
graft rejection in a nonmyeloablative setting. Blood.
108:2114–2120. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Y and Lin F: Mesenchymal stem cells are
injured by complement after their contact with serum. Blood.
120:3436–3443. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Blasius AL and Beutler B: Intracellular
toll-like receptors. Immunity. 32:305–315. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen JC, Ng MM and Chu JJ: Activation of
TLR2 and TLR6 by Dengue NS1 protein and its implications in the
immunopathogenesis of Dengue virus infection. PLoS Pathog.
11:e10050532015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fu YS, Cheng YC, Lin MY, Cheng H, Chu PM,
Chou SC, Shih YH, Ko MH and Sung MS: Conversion of human umbilical
cord mesenchymal stem cells in Wharton's jelly to dopaminergic
neurons in vitro: Potential therapeutic application for
parkinsonism. Stem Cells. 24:115–124. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tolar J, Le Blanc K, Keating A and Blazar
BR: Concise review: Hitting the right spot with mesenchymal stromal
cells. Stem Cells. 28:1446–1455. 2011. View
Article : Google Scholar
|
|
20
|
Akira S, Uematsu S and Takeuchi O:
Pathogen recognition and innate immunity. Cell. 124:783–801. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
DelaRosa O and Lombardo E: Modulation of
adult mesenchymal stem cells activity by toll-like receptors:
Implications on therapeutic potential. Mediators Inflamm.
2010:8656012010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang L, Liu D, Pu D, Wang YW, Li L, He
YQ, Li YL, Li L and Li WM: The TLR7 agonist Imiquimod promote the
immunogenicity of mesenchymal stem cessl. Biol Res. 48:62015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang L, Liu D, Pu D, Wang YW, Li L, He Y,
Li YL, Li L, Qiu ZC, Zhao S and Li WM: The role of Toll-like
receptor 3 and 4 in regulating the function of mesenchymal stem
cells isolated from umbilical cord. Int J Mol Med. 35:1003–1010.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang Y, Wang Y, Li L, Bao J, Chen F and
Zhang L: Toll-like receptor 9 agonist stimulation enables
osteogenic differentiation without altering the immune status of
umbilical cord mesenchymal stem cells. Mol Med Rep. 12:8077–8084.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang XP, Sun Z, Miyagi Y, McDonald
Kinkaid H, Zhang L, Weisel RD and Li RK: Differentiation of
allogeneic mesenchymal stem cells induces immunogenicity and limits
their long-term benefits for myocardial repair. Circulation.
122:2419–2429. 2010. View Article : Google Scholar : PubMed/NCBI
|
